CCHT(SZ:000661) Ge Long Hui·2025-11-12 09:07Core Viewpoint - Changchun High-tech's subsidiary, Baike Biological, has received approval from the National Medical Products Administration for clinical trials of its acellular combined diphtheria, tetanus, and pertussis vaccine for adolescents and adults, addressing the rising incidence of whooping cough among this demographic [1][2]. Group 1 - The approved vaccine is designed to prevent whooping cough, diphtheria, and tetanus in individuals aged 10 and above, stimulating immune responses to prevent invasive infections [1]. - There has been an increasing trend in the incidence of whooping cough among adolescents and adults both domestically and internationally, prompting recommendations for vaccination every 10 years in developed countries [1]. - Currently, China's immunization program primarily targets infants, with no approved combined diphtheria, tetanus, and pertussis vaccine for adolescents and adults [1]. Group 2 - The vaccine developed by Baike Biological utilizes a new formulation that includes inactivated pertussis toxin, filamentous hemagglutinin, diphtheria toxin, and tetanus toxin, along with an aluminum-CpG adjuvant system to enhance immune response [2]. - If the clinical trials are successful and the vaccine is approved for market release, it will enhance the company's vaccine research pipeline and diversify its product offerings, contributing to overall business growth and providing high-quality vaccination options to the public [2].